Chulalongkorn Medical Journal


Angiopoietin-like protein 3 (ANGPTL3) has emerged as important regulators of lipid metabolism. Current innovative therapeutic options using monoclonal antibodies, antisense oligonucleotide (ASO) or vaccine approaches to block this protein may minimize the risk of atherosclerosis in dyslipidemic individuals. The purpose of this review is to discuss the effectiveness of these new ANGPTL3 inhibitors.





To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.